179. Ocrelizumab Subcutaneous Injection in Patients with Multiple Sclerosis: Further Characterisation of the Benefit–risk Profile from the OCARINA Clinical Development Programme
| Autor: | Newsome, S.D. 1, Krzystanek, E. 2, Selmaj, K. 3, 4, Goldstick, L. 5, Bermel, R. 6, Figueiredo, C. 7, Townsend, B. 7, Augustin, A. 8, Zecevic, D. 7, Giacobino, C. 7, Schneble, H.M. 7, Bortolami, O. 7, Shen, Y.-A. 9, Centonze, D. 10, 11 |
|---|---|
| Zdroj: | In Multiple Sclerosis and Related Disorders December 2024 92 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect